Sensyne Health (LON:SENS) had its target price decreased by Peel Hunt from GBX 262 ($3.45) to GBX 195 ($2.57) in a research note released on Tuesday morning, Stock Target Advisor reports. Peel Hunt currently has a buy rating on the stock.
Separately, Liberum Capital restated a buy rating on shares of Sensyne Health in a research report on Tuesday, January 21st.
LON:SENS opened at GBX 54.50 ($0.72) on Tuesday. The company’s 50-day moving average price is GBX 57.58 and its 200-day moving average price is GBX 102.18. The company has a current ratio of 10.89, a quick ratio of 10.70 and a debt-to-equity ratio of 3.88. The company has a market cap of $70.07 million and a P/E ratio of -3.78. Sensyne Health has a twelve month low of GBX 35.30 ($0.46) and a twelve month high of GBX 190 ($2.50).
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts.
Read More: How to build a Fibonacci channel
Receive News & Ratings for Sensyne Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensyne Health and related companies with MarketBeat.com's FREE daily email newsletter.